New combo therapy aims to shrink prostate cancer tumors

NCT ID NCT07190300

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called tulmimetostat combined with standard hormone therapies (darolutamide or abiraterone) in men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination is safe and works better than standard care alone. About 181 men will take part, first in a small dose-finding phase, then in a larger phase comparing the combo to darolutamide alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Kennedy disease metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)

Contacts and locations

Locations

Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States
Medical University of South Carolina MUSC
RECRUITING

Charleston, South Carolina, 29425, United States
Novartis Investigative Site
WITHDRAWN

Camperdown, New South Wales, 2050, Australia
Novartis Investigative Site
RECRUITING

Wollongong, New South Wales, 2500, Australia
Novartis Investigative Site
RECRUITING

Porto Alegre, Rio Grande do Sul, 90610-001, Brazil
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H2X 1R9, Canada
Novartis Investigative Site
RECRUITING

Guangzhou, 510060, China
Novartis Investigative Site
RECRUITING

Créteil, 94010, France
Novartis Investigative Site
RECRUITING

Lille, 59020, France
Novartis Investigative Site
RECRUITING

Nantes, 44093, France
Novartis Investigative Site
RECRUITING

Jena, Thuringia, 07740, Germany
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

Hong Kong, 999077, Hong Kong
Novartis Investigative Site
RECRUITING

Budapest, H 1122, Hungary
Novartis Investigative Site
RECRUITING

Budapest, H-1083, Hungary
Novartis Investigative Site
RECRUITING

Szeged, 6725, Hungary
Novartis Investigative Site
RECRUITING

Rozzano, MI, 20089, Italy
Novartis Investigative Site
RECRUITING

Verona, VR, 37134, Italy
Novartis Investigative Site
RECRUITING

Seoul, 05505, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 06591, South Korea
Novartis Investigative Site
RECRUITING

Madrid, 28034, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28040, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28222, Spain
Novartis Investigative Site
RECRUITING

Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

London, W1G 6AD, United Kingdom
Uni Of Iowa Hospitals And Clinics
RECRUITING

Iowa City, Iowa, 52242, United States
Univ of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294-3300, United States
University of Kansas Cancer Center
RECRUITING

Westwood, Kansas, 66205, United States
Wichita Urology Group PA
RECRUITING

Wichita, Kansas, 67226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.